MedTrace Logo

ENX-104 MAD Study for Participants With Major Depressive Disorder With Anhedonia (aMDD)

NCT07253324 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-12-31

No results posted yet for this study

Summary

The study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ENX-104 in participants with major depressive disorder with anhedonia (aMDD).

Conditions

Interventions

DRUG

ENX-104

Oral Solution

DRUG

Placebo

Oral solution

Sponsors & Collaborators

  • Engrail Therapeutics INC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-17
Primary Completion
2025-11-26
Completion
2025-11-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07253324 on ClinicalTrials.gov